Nedaplatin
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Mithracin · Plica
Antitumor antibiotic · approved 1970 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An older antitumor antibiotic and bone-resorption inhibitor with cumulative, dose-limiting renal tubular toxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Cumulative, dose-related nephrotoxicity is a recognized dose-limiting toxicity; when used for hypercalcemia, its antiresorptive potency can overshoot to symptomatic hypocalcemia. Precise modern incidence is not well quantified because the drug is now essentially obsolete. The comparative hypercalcemia-tolerability review cited here pooled trials of at least 10 patients and reported serum creatinine elevation in 5% of plicamycin-treated patients, alongside hepatotoxicity in 26% and nausea/vomiting in 23%. The creatinine figures it gives for etidronate (8%), clodronate (5%) and pamidronate (2%) are bisphosphonate rates from the same review and are not plicamycin's.Source: Zojer, Drug Saf 1999
With repeated / cumulative dosing (days to weeks).
Distilled from: “With repeated / cumulative dosing (days to weeks).”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Dose-dependent acute tubular injury / AKI; nephrotoxicity reported even after a single 25 microgram/kg dose, with pre-existing renal impairment magnifying the effect. Cumulative-dose renal toxicity historically limited its use. PMID 6227249 (opens PubMed in a new tab)
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative incidence
Acute Tubular Necrosis strikes: Proximal Tubule, Distal Tubule / Collecting Duct.
Acute Tubular Necrosis
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Aureolic-acid antitumor antibiotic that binds GC-rich DNA in the minor groove (in a magnesium-dependent fashion), displacing Sp1-family transcription factors and inhibiting RNA and protein synthesis. It also potently inhibits osteoclastic bone resorption, the basis of its historical use for hypercalcemia. Historically used for testicular germ-cell tumors and hypercalcemia of malignancy / Paget disease.
Class-level context for the major non-renal toxicities of the Antitumor antibiotic class.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Hematologic
Cytopenias, thrombosis, TMA
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 1 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
1 report is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1 of the 1 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
No organ-classified adverse-event terms among this agent's top reports.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Plicamycin (mithramycin) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Pepaxto · Peptide-conjugated alkylator
Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.
Emrelis · c-Met ADC (MMAE)
c-Met MMAE antibody-drug conjugate; proximal tubular ATN risk extrapolated from the ADC/MMAE class.
Yondelis · Marine alkylating agent
Rhabdomyolysis → pigment nephropathy; hepatotoxicity.
Padcev · Antibody-drug conjugate (Nectin-4/MMAE)
Emerging AKI and electrolyte signals in urothelial cancer.
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.